Records containing: Narcolepsy With Cataplexy
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-10-30A Double-blind, Placebo-Controlled, Randomized Withdrawal Trial to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy With Cataplexy (Narcolepsy Type 1)
-
CLINICAL_TRIALS study record update · 2026-09-01A Double-blind, Placebo-Controlled, Randomized Withdrawal Trial to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy With Cataplexy (Narcolepsy Type 1)
-
CLINICAL_TRIALS study record update · 2026-03-20A Double-blind, Placebo-Controlled, Randomized Withdrawal Trial to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy With Cataplexy (Narcolepsy Type 1)
-
CLINICAL_TRIALS study record update · 2026-03-10Imagery Rehearsal Therapy for the Treatment of Nightmares in Narcolepsy: A Pilot Randomized Controlled Trial
-
CLINICAL_TRIALS study record update · 2025-07-16Antibiotic-mediated Improvements in Vigilance: Mechanisms of Action of Clarithromycin in Hypersomnia Syndromes
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2024-09-19Double Blind, Multicentre, Randomized, Placebo-controlled Trial to Evaluate Safety and Efficacy of Pitolisant in Children From 6 to Less Than 18 Years With Narcolepsy With/Without Cataplexy, Followed by a Prolonged Open-label Period
-
CLINICAL_TRIALS study record update · 2024-06-12Behavioral Treatment of Narcolepsy-Related Nightmares
-
CLINICAL_TRIALS study record update · 2024-05-21A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of NLS-2 (Mazindol Extended-Release) Tablets in the Treatment of Narcolepsy Type 1
-
CLINICAL_TRIALS study record update · 2023-11-01Mind-Body Approach to Improve Health-Related Quality of Life for People With Narcolepsy
-
CLINICAL_TRIALS study record update · 2023-03-13A 6-Month Multicenter, Open-Labelled Extension of the Clinical Trial NLS-1021 in Narcoleptic Patients With and Without Cataplexy
-
CLINICAL_TRIALS study record update · 2022-04-08Single Center, Therapeutic Exploratory Clinical Trial to Evaluate the Safety of Sodium Oxybate (Xyrem) 500 mg/mL Oral Solution on Potential Endocrine Changes at Currently Labeled Therapeutic Dose Regimens (4.5 - 9 g/Day Divided Into Two Equal Doses) During 12 Weeks of Treatment of Cataplexy in Adult Patients With Narcolepsy.
-
CLINICAL_TRIALS study record update · 2021-03-23Does Xyrem Influence Brain Dopamine in Patients With Narcolepsy? A PET Imaging Investigation
-
CLINICAL_TRIALS study record update · 2020-11-12A Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy
-
CLINICAL_TRIALS study record update · 2020-06-05'A Profile of Physical Performance Variables in an Out-patient Adult Population With Narcolepsy'
-
CLINICAL_TRIALS study record update · 2019-08-28An Open Label Expanded Access Program Intended to Provide Treatment With HBS-101 (Pitolisant) to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy
-
CLINICAL_TRIALS study record update · 2019-04-30ClinicalTrials.gov study NCT02221869
-
CLINICAL_TRIALS study record update · 2016-08-31A Randomized, Double Blind Study Comparing Pitolisant (BF2.649) to Placebo in Two Parallel Groups on the Weekly Frequency of Cataplexy Attacks and Excessive Daytime Sleepiness in Narcoleptic Patients With Cataplexy.